glp-1/gip/glucagon triple agonist name Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research PDB-101: Molecule of the Month:
Description
One study (SURPASS-2) specifically compared Mounjaro 5 mg, 10 mg, and 15 mg to low-dose semaglutide (1 mg) in people with type 2 diabetes
doi: 10.1530/EJE-09-0101
Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA
However, many women with PCOS and obesity have a more difficult time losing weight than the average woman, due to insulin resistance
The analogs of 7 created in this manner were tested for DPP-8 and DPP-9 activity, as well as for activity against DPP-4 and DPP-2
